All In Biotech

Drug Trial Radar · NCT04513925

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation

Last checked: Nov 20, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 829 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

829

Actual

Start

Aug 24, 2020

Primary completion

May 27, 2025

Study completion Jul 31, 2025

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Aug 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in participants with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC) who have received at least two cycles of concurrent platinum-based chemoradiotherapy (CRT) and have not had radiographic disease progression.

Conditions

  • Non-small Cell Lung Cancer (NSCLC)

Interventions

  • AtezolizumabDrug

    Atezolizumab 1680 mg every 4 weeks (Q4W) will be administered IV on Day 1 of each 28-day cycle.

  • TiragolumabDrug

    Tiragolumab 840 mg Q4W will be administered IV on Day 1 of each 28-day cycle.

  • DurvalumabDrug

    Durvalumab will be administered based on weight at 10 mg/kg IV every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle, or will be administered at a fixed dose of 1500 mg IV every 4 weeks (Q4W) (for participants whose weight \>/= 30 kg) on Day 1 of each 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS), as Assessed by an Independent Review Facility (IRF) in Programmed Death-ligand 1 (PD-L1) Positive Analysis Set (PPAS)Time frame: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 57 months)
  2. PFS, as Assessed by an IRF in FASTime frame: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 57 months)

Locations

189 sites in 26 countries. Site status is shown where the registry gives one.

  • Stanford University

    Palo Alto, California

  • Banner MD Anderson Cancer Center

    Greeley, Colorado

  • Florida Cancer Specialists

    Fort Myers, Florida

  • Cancer Care Centers of Brevard

    Palm Bay, Florida

  • Woodlands Medical Specialists, P.A.

    Pensacola, Florida

  • Florida Cancer Specialist, North Region

    St. Petersburg, Florida

  • Northwest Georgia Oncology Centers PC - Marietta

    Marietta, Georgia

  • Illinois Cancer Care

    Peoria, Illinois

  • New England Cancer Specialists

    Brunswick, Maine

  • Southcoast Health System

    Fairhaven, Massachusetts

  • Minnesota Oncology Hematology

    Minneapolis, Minnesota

  • HCA Midwest Health

    Kansas City, Missouri

  • Cox Health Systems

    Springfield, Missouri

  • Optum Health Care

    Las Vegas, Nevada

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Titan Health Partners LLC, d/b/a Astera Cancer Care

    East Brunswick, New Jersey

  • San Juan Oncology Associates

    Farmington, New Mexico

  • New York Oncology Hematology,P.C.-Albany

    Albany, New York

  • Mount Sinai Medical Center

    New York, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Prisma Health ? Upstate

    Greenville, South Carolina

  • Tennessee Oncology Chattanooga

    Chattanooga, Tennessee

  • Sarah Cannon Research Institute / Tennessee Oncology

    Nashville, Tennessee

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Virginia Oncology Associates

    Norfolk, Virginia

  • CEMIC

    Buenos Aires, Argentina

  • Hospital Britanico de Buenos Aires

    Ciudad Autonoma Buenos Aires, Argentina

  • Clinica Universitaria Reina Fabiola

    Córdoba, Argentina

  • Sanatorio Parque S.A.

    Rosario, Argentina

  • Blacktown Hospital

    Blacktown, New South Wales, Australia

  • Macarthur Cancer Therapy Centre

    Campbelltown, New South Wales, Australia

  • St George Hospital

    Kogarah, New South Wales, Australia

  • Flinders Medical Centre

    Bedford Park, South Australia, Australia

  • Monash Health Translational Precinct

    Victoria, Victoria, Australia

  • Fiona Stanley Hospital

    Bull Creek, Western Australia, Australia

  • Tiroler Landeskrankenanstalten Ges.M.B.H.

    Innsbruck, Austria

  • Kepler Universitätskliniken GmbH - Med Campus III

    Linz, Austria

  • Klinik Penzing

    Vienna, Austria

  • GHdC Site Les Viviers

    Charleroi, Belgium

  • AZ Maria Middelares

    Ghent, Belgium

Showing 40 of 189 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.